- Home
- EXEL vs OKLO Comparison
EXEL vs OKLO Comparison
Compare EXEL & OKLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- OKLO
- Stock Information
- Founded
- EXEL 1994
- OKLO 2013
- Country
- EXEL United States
- OKLO United States
- Employees
- EXEL N/A
- OKLO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- OKLO
- Sector
- EXEL Health Care
- OKLO
- Exchange
- EXEL Nasdaq
- OKLO NYSE
- Market Cap
- EXEL 11.3B
- OKLO 9.4B
- IPO Year
- EXEL 2000
- OKLO N/A
- Fundamental
- Price
- EXEL $44.08
- OKLO $55.68
- Analyst Decision
- EXEL Buy
- OKLO Strong Buy
- Analyst Count
- EXEL 18
- OKLO 9
- Target Price
- EXEL $43.00
- OKLO $58.14
- AVG Volume (30 Days)
- EXEL 3.3M
- OKLO 22.7M
- Earning Date
- EXEL 08-05-2025
- OKLO 08-12-2025
- Dividend Yield
- EXEL N/A
- OKLO N/A
- EPS Growth
- EXEL 237.58
- OKLO N/A
- EPS
- EXEL 2.20
- OKLO N/A
- Revenue
- EXEL $2,298,922,000.00
- OKLO N/A
- Revenue This Year
- EXEL $9.37
- OKLO N/A
- Revenue Next Year
- EXEL $11.05
- OKLO N/A
- P/E Ratio
- EXEL $19.98
- OKLO N/A
- Revenue Growth
- EXEL 24.49
- OKLO N/A
- 52 Week Low
- EXEL $21.82
- OKLO $5.35
- 52 Week High
- EXEL $49.62
- OKLO $73.55
- Technical
- Relative Strength Index (RSI)
- EXEL 57.96
- OKLO 54.26
- Support Level
- EXEL $42.66
- OKLO $55.35
- Resistance Level
- EXEL $49.62
- OKLO $64.78
- Average True Range (ATR)
- EXEL 1.58
- OKLO 6.73
- MACD
- EXEL 0.10
- OKLO -1.38
- Stochastic Oscillator
- EXEL 43.24
- OKLO 34.92
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.